Application of Licochalcone A in preparation of antiallergic drug

A licorice chalcone and anti-allergic technology, which is applied in drug combinations, allergic diseases, pharmaceutical formulations, etc., can solve problems such as the application of anti-allergic drugs that have not been reported, and achieve the reduction of mast cell degranulation, improvement of symptoms, and relief of local and systemic allergy reaction symptoms

Inactive Publication Date: 2021-09-28
XIAN HONGHUI HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Prior art studies have reported that licochalcone A has anti-inflammatory, anti-cancer, anti-tumor, antibacterial, in vivo metabolism, anti-malarial and anti-parasitic effects, but there is no reference to licochalcone A as an anti-allergic Drug-related application reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Licochalcone A in preparation of antiallergic drug
  • Application of Licochalcone A in preparation of antiallergic drug
  • Application of Licochalcone A in preparation of antiallergic drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Licochalcone A inhibits mouse toe swelling and Evans blue exudation caused by OVA

[0026] 1. Experimental materials

[0027] Ovalbumin (OVA was purchased from SIGMA Company), 6-8 week-old male C57 mice (purchased from the Experimental Animal Center of Xi'an Jiaotong University), licochalcone A (purchased from Baoji Chenguang), 0.4% Evans blue solution, 3.5% chloral hydrate solution, PBS solution, normal saline, acetone.

[0028] The structural formula of the licochalcone A is as follows:

[0029]

[0030] 2. Experimental method

[0031] The mice were divided into blank control group, positive control group and licochalcone A administration groups of various concentrations. The rats were sensitized by intraperitoneal injection of 20 μg / mL OVA solution one week in advance. Licochalcone A solutions of different concentrations (respectively 20 mg / kg, 40 mg / kg, 80 mg / kg) were prepared with 0.5% CMC-Na solution for intragastric administration. After 30 minu...

Embodiment 2

[0034] Example 2 Licochalcone A inhibits OVA-induced hypothermia in mice

[0035] 1. Experimental materials

[0036] OVA (purchased from SIGMA Company), 6-8 week-old male C57 mice (purchased from the Experimental Animal Center of Xi'an Jiaotong University), licochalcone A (purchased from Baoji Chenguang), and a mouse thermometer.

[0037] 2. Experimental method

[0038] The mice were divided into blank control group, positive control group and licochalcone A administration groups of various concentrations. The rats were sensitized by intraperitoneal injection of 20 μg / mL OVA solution one week in advance. Licochalcone A solutions of different concentrations (respectively 20 mg / kg, 40 mg / kg, 80 mg / kg) were prepared with 0.5% CMC-Na solution for intragastric administration. After 30 minutes, 100 μg / mL OVA solution was injected into the tail vein, and the blank control group was injected with an equal volume of normal saline. The rectal temperature of the mouse was detected ev...

Embodiment 3

[0041] Example 3 Licochalcone A inhibits mouse mast cell degranulation

[0042] 1. Experimental materials

[0043] Male C57 mice aged 6-8 weeks (purchased from the Experimental Animal Center of Xi'an Jiaotong University), Licochalcone A (purchased from Baoji Chenguang), and mouse β-aminoglycoside substrate kit (purchased from Beijing Yiqiao).

[0044] A fully automatic microplate reader was purchased from Bio-Rad (California, USA).

[0045] Cell line: Mouse peritoneal mast cell PBMC cultured in 5% CO 2 , in an environment of 37°C. The medium was half-replaced with fresh medium every week to maintain the cells at 2 × 10 6 density of cells per milliliter. TM buffer solution (composition (g / L): 6.954 NaCl, 0.353 KCl, 2.383 HEPES, 0.162 KH 2 PO 4 , 0.282 CaCl 2, 0.143 MgSO 4 , 0.991 glucose, 1 bovine serum albumin. Triton X-100 was purchased from Kehao Bioengineering Company (Xi'an, China), D-glucose Tianjin Kemiou Chemical Reagent Company (Tianjin, China), bovine serum a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of Licochalcone A in preparation of an antiallergic drug. A to-be-detected drug group, a normal saline control group and a normal control group are evaluated by comparing a mastocyte degranulation degree, a mouse toe swelling degree, a toe Evans blue exudation degree and a body temperature lowering degree, so that the treatment effect of the drug for allergic diseases is evaluated; a result determines that the Licochalcone A can be used for preparing the antiallergic drug. The Licochalcone A can effectively relieve local and systemic anaphylactic reaction symptoms of mice. Mastocyte degranulation is reduced, and symptoms caused by allergy are remarkably eliminated.

Description

technical field [0001] The invention belongs to the technical field of preparation of antiallergic drugs, and relates to the application of licochalcone A in the preparation of antiallergic drugs. Background technique [0002] An allergic reaction is a type of immune response of the body. Generally, it refers to the adverse reaction triggered by antigen (or hapten) re-entering the sensitized body and combining with its specific antibody. Allergic reactions require repeated exposure to antigens. During the first exposure, the sensitization process is completed by causing lymphocytes in the body to produce specific IgE to the antigen; when the body is exposed to the antigen again, the antigen binds to the IgE on the surface of mast cells to cause an allergic reaction happened. The whole process requires both innate and adaptive immunity. It is related to the degranulation of mast cells or basophils, activation of the complement system, and the release of bioactive mediators...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/12A61K36/484A61P37/08
CPCA61K31/12A61K36/484A61P37/08
Inventor 鲁超郭浩舒瑾宇文星刘鑫陈颖璞王宝辉
Owner XIAN HONGHUI HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap